Holen Sie sich die Stockscreener-App
3.58
2.98%
-0.11
Schlusskurs vom Vortag:
$3.69
Offen:
$3.65
24-Stunden-Volumen:
27,039
Relative Volume:
0.99
Marktkapitalisierung:
$19.15M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-16.35M
KGV:
-1.1738
EPS:
-3.05
Netto-Cashflow:
$-11.88M
1W Leistung:
-10.28%
1M Leistung:
+15.48%
6M Leistung:
-30.49%
1J Leistung:
-45.26%
1-Tages-Spanne:
$3.56
$3.89
1-Wochen-Bereich:
$3.40
$4.03
52-Wochen-Spanne:
$2.6838
$11.79
Lipocine Inc Stock (LPCN) Company Profile
Firmenname
Lipocine Inc
Sektor
Branche
Telefon
801 994 7383
Adresse
675 ARAPEEN DRIVE, SUITE 202, SALT LAKE CITY, UT
Vergleichen Sie LPCN mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LPCN
Lipocine Inc
|
3.58 | 21.35M | 0 | -16.35M | -11.88M | -3.05 |
|
ONC
Beigene Ltd Adr
|
241.43 | 27.03B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
436.00 | 112.64B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.335 | 40.86M | 0 | 0 | 0 | 0.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
588.34 | 64.17B | 14.09B | 4.50B | 2.96B | 39.28 |
|
VRNA
Verona Pharma Plc Adr
|
75.06 | 6.07B | 0 | -153.72M | -103.81M | -2.00 |
Lipocine Inc Stock (LPCN) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2021-06-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-12-10 | Hochstufung | Ladenburg Thalmann | Neutral → Buy |
| 2018-01-12 | Bestätigt | H.C. Wainwright | Buy |
| 2018-01-11 | Herabstufung | Canaccord Genuity | Buy → Hold |
| 2017-12-08 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-07 | Eingeleitet | H.C. Wainwright | Buy |
| 2015-07-22 | Eingeleitet | ROTH Capital | Buy |
| 2015-06-23 | Eingeleitet | Canaccord Genuity | Buy |
Alle ansehen
Lipocine Inc Aktie (LPCN) Neueste Nachrichten
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology - Nasdaq
Lipocine’s LPCN 1148 Gains Fast Track Designation - TipRanks
Lipocine's LPCN 1148 Highlighted in the June 2025 Edition of Hepatology | State News | hjnews.com - The Herald Journal
Lipocine (NASDAQ:LPCN) Share Price Passes Below 200 Day Moving Average – Time to Sell? - Defense World
StockNews.com Initiates Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine to Present at A.G.P.'s Annual Healthcare Company Showcase - Longview News-Journal
Lipocine to Present at A.G.P. Healthcare Showcase - TipRanks
Lipocine Reveals Next-Gen Oral Drug Delivery Platform at Major Healthcare ConferenceKey Developments Expected - Stock Titan
Lipocine Updates Corporate Presentation for Stakeholders - TipRanks
Lipocine To Present At H.C. Wainwright Annual Neuropsychiatry Virtual Conference - Barchart.com
Lipocine: Q1 Earnings Snapshot - CT Insider
Lipocine Inc. Reports Earnings Results for the First Quarter Ended March 30, 2025 - marketscreener.com
Lipocine Reports Q1 2025 Financial Results - TipRanks
Lipocine Inc. SEC 10-Q Report - TradingView
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2025 - Morningstar
Renaissance Technologies LLC Sells 4,300 Shares of Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine announces license and supply agreement with Ache - TipRanks
Lipocine Announces License and Supply Agreement for TLANDO® in Brazil - Eagle-Tribune
Lipocine Partners with Aché for TLANDO® in Brazil - TipRanks
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock Ne - GuruFocus
Lipocine partners with Aché to market TLANDO in Brazil By Investing.com - Investing.com Canada
Lipocine partners with Aché to market TLANDO in Brazil - Investing.com
LPCN Secures Licensing Deal for TLANDO in Brazil | LPCN Stock News - GuruFocus
Lipocine Targets Booming Brazil Testosterone Market with Exclusive TLANDO License Deal as Growth Hits 34% - Stock Titan
Lipocine Inc expected to post a loss of 35 cents a shareEarnings Preview - TradingView
Geode Capital Management LLC Boosts Holdings in Lipocine Inc. (NASDAQ:LPCN) - Defense World
Lipocine (NASDAQ:LPCN) Coverage Initiated by Analysts at StockNews.com - Defense World
Lipocine Announces Financial Results for the First Quarter Ended March 31, 2023 - Seeking Alpha
Press Release Distribution & PR Platform - ACCESS Newswire
Sarcopenia Clinical Trial Pipeline Appears Robust With 18+ Key Pharma Companies Actively Working in the Therapeutics Segment | DelveInsight - GlobeNewswire Inc.
StockNews.com Begins Coverage on Lipocine (NASDAQ:LPCN) - Defense World
Lipocine Receives Updated Regulatory Guidance on LPCN 1154 (PR Newswire) - Aktiellt
Lipocine (NASDAQ:LPCN) Coverage Initiated at StockNews.com - Defense World
Lipocine Inc. Reports 2024 Financial Turnaround - TipRanks
Lipocine’s Phase III trial of LPCN 1154 to begin for postpartum depression - Yahoo
Lipocine Announces Initiation of Outpatient Phase 3 Postpartum Depression Trial of LPCN 1154 - MarketScreener
Revolutionary At-Home Postpartum Depression Drug Enters Final Testing Phase - Stock Titan
Testosterone, TRAVERSE, And A Label Change 15 Years In The Making - News & Insights
Lipocine Announces Financial Results for the Full Year Ended December 31, 2024 - Quantisnow
Lipocine Turns Profitable: How $11.2M in Licensing Deals Transformed 2024 Results - StockTitan
Lipocine to change FDA labeling for testosterone products -March 12, 2025 at 09:59 am EDT - Marketscreener.com
Lipocine Announces FDA Labeling Changes for Testosterone Products - Citizentribune
Finanzdaten der Lipocine Inc-Aktie (LPCN)
Umsatz
Nettogewinn
Free Cashflow
ENV
17.27%
1.06%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):